1,693 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by IPG Investment Advisors LLC

Key Points

• IPG Investment Advisors LLC has acquired 1,693 shares of Eli Lilly and Company (NYSE: LLY), valued at approximately $1,398,000, during the first quarter of 2023.
• Eli Lilly reported earnings of $3.34 per share for the quarter, missing analysts' expectations, with a year-over-year revenue increase of 45.2% to $12.73 billion.
• The company recently announced a quarterly dividend of $1.50 per share, representing an annualized dividend of $6.00 and a yield of 0.8%.

IPG Investment Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,693 shares of the company's stock, valued at approximately $1,398,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. MWA Asset Management boosted its holdings in Eli Lilly and Company by 11.0% in the first quarter. MWA Asset Management now owns 372 shares of the company's stock worth $307,000 after purchasing an additional 37 shares during the last quarter. ING Groep NV boosted its holdings in Eli Lilly and Company by 22.8% in the first quarter. ING Groep NV now owns 131,811 shares of the company's stock worth $108,864,000 after purchasing an additional 24,475 shares during the last quarter. Earned Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 356.5% in the first quarter. Earned Wealth Advisors LLC now owns 2,689 shares of the company's stock worth $2,221,000 after purchasing an additional 2,100 shares during the last quarter. SGL Investment Advisors Inc. boosted its holdings in Eli Lilly and Company by 30.8% in the first quarter. SGL Investment Advisors Inc. now owns 399 shares of the company's stock worth $300,000 after purchasing an additional 94 shares during the last quarter. Finally, Allianz SE boosted its holdings in Eli Lilly and Company by 3.5% in the first quarter. Allianz SE now owns 39,201 shares of the company's stock worth $32,376,000 after purchasing an additional 1,324 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $761.47 on Monday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a market cap of $721.68 billion, a P/E ratio of 61.96, a P/E/G ratio of 1.08 and a beta of 0.44. The firm's fifty day moving average is $775.51 and its two-hundred day moving average is $800.52. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the firm posted $2.58 earnings per share. The business's revenue was up 45.2% on a year-over-year basis. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 48.82%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Guggenheim increased their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research note on Friday, July 11th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.